Lauren Lockwood
Advanced Practice Midwife · Oakland, CANPI 1356777130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Among advanced practice midwife clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$364
- Therapeuticsmd, Inc.$182
- Organon$131
- Astellas Pharma US Inc$128
- Biogen$128
- Pfizer$97
- plus $724 from 19 others
What the payments were for
- Food & beverage$1,74099%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $364 |
| Therapeuticsmd, Inc. | 16 | $182 |
| Organon | 7 | $131 |
| Astellas Pharma US Inc | 6 | $128 |
| Biogen | 5 | $128 |
| Pfizer | 4 | $97 |
| Evofem Biosciences, Inc. | 5 | $91 |
| Hologic Sales And Service, LLC | 3 | $83 |
| Exeltis, USA Inc. | 3 | $65 |
| Dexcom, Inc. | 3 | $65 |
| Mayne Pharma Commercial LLC | 6 | $56 |
| BD | 2 | $53 |
| Bayer | 2 | $38 |
| Coopersurgical, Inc. | 2 | $37 |
| Shield Therapeutics Inc | 2 | $37 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Lilly USA, LLC | 1 | $25 |
| Arcutis Biotherapeutics, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Myovant Sciences Inc. | 1 | $20 |
| Mylan Pharmaceuticals Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Avion Pharmaceuticals | 1 | $14 |
| Millicent US Inc | 1 | $13 |
| Ascend Therapeutics US, LLC | 1 | $13 |
How this compares
$1,753 in reported general payments places this provider in the 95th percentile of 451 advanced practice midwife providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 11 | $5,662 |
| Estradiol | 56 | $3,767 |
| ValacyclovirValacyclovir Hcl | 14 | $517 |
| ProgesteroneProgesterone, Micronized | 30 | $297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $97 | $5,66211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 451 advanced practice midwife providers in California.
Other advanced practice midwife in Oakland
- Candace MooneyTemecula$32K
- Jeri SanchezMoreno Valley$13K
- Faye BatesVisalia$8K
- Anne LeeFallbrook$5K
- Andrea Dorwart CraneIrvine$5K
- Olga LibovaMountain View$5K
- Journey TalkovicSanta Cruz$4K
- Jodie TorromeoLong Beach$3K
- Carla BushSan Bernardino$3K
- Nancy SelixMill Valley$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.